Intellia Therapeutics, Inc. (NASDAQ:NTLA) traded at $22.27 at last check on Tuesday, Sep 15, making an upward move of 6.48% on its previous day’s price.
Looking at the stock we see that its previous close was $20.92 and the beta (5Y monthly) reads 1.7 with the day’s price range being $20.87 – 22.87. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, NTLA has a high of $25.56 and a low of $9.18. The company’s stock has gained about 11.97% over that past 30 days.
Intellia has a market cap of $1.29 Billion and is expected to release its quarterly earnings report on August 06, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the NTLA stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.59, with the EPS growth for the year declined at -$2.46 for 2020 and -$3.04 for next year. These figures represent 0.17% and at 0.24% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $15.38 Million, with a low of $5.42 Million and a high of $29.4 Million. The median projection represents growth adding up to 44.9% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $59.04 Million, or +37% up from figures reported last year.
On the other hand, looking at the outlook for the NTLA stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 11 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 4 have rated the Intellia Therapeutics, Inc. (NTLA) stock as a Hold, while 5 rate it as a Buy. 2 analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the NTLA stock currently stands at 0, and the current price level is 10.32% off its SMA20 and 8.29% from its 50-day simple moving average. The RSI (14) is pointing at 60.4 while the volatility over the past week is 7.09% and drops to 6.47% over the past one month. The beta value is 1.7, while the average true range (ATR) is currently pointing at 1.36. The average price target for the stock over the next 12 months is $24.75, with the estimates having a low of $16 and a high of $37. These price ends are -28.15% and +66.14% off the current price level respectively, although investors could be excited at the prospect of a +1.03% if the NTLA share price touches on the median price of $22.5.
Let’s briefly compare Intellia (NTLA) stock to its peers. We find that today’s price change of +6.48% and +52.12% over the past 12 months for NTLA betters that of Amgen Inc (AMGN), which has seen its stock price rise 0.65% in the latest trading session and is +27.96% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has dropped -0.28% today, and is +20.34% up over the past year, while Gilead Sciences Inc (GILD) is also up 6.48% yet its price remains in the green at 52.12% over the same period. Amgen has a P/E ratio of 20.29 compared to Intellia’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.52% and 0.01%, respectively, in early deals.
Coming back to Intellia Therapeutics, Inc. (NASDAQ:NTLA), we note that the average 3-month trading volume was 792.48 Million, while that of the preceding 10-day period stands at 711.42 Million. Current shares outstanding are 58.74 Million.
According to data from Thomson Reuters, insiders hold 19.02% of the company’s shares while institutions hold 76.41%. The data shows that short shares as of August 30, 2020, stood at 10.88 Million at a short ratio of 15.62. This represents a 18.53% Short interest in Shares outstanding on August 30, 2020. Shares short rose in August from the previous month at 10.77 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +51.81% up in year-to-date price movement.